Stock EXEL EXELIXIS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Exelixis, Inc.

Equities

EXEL

US30161Q1040

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-19 pm EDT 		5-day change 1st Jan Change
22.52 USD +0.13% Intraday chart for Exelixis, Inc. -1.27% -6.13%
Apr. 12 North American Morning Briefing : Big Banks Kick -2- DJ
Apr. 11 Barclays Downgrades Exelixis to Equalweight From Overweight, Price Target is $25 MT

Evolution of the average Target Price on Exelixis, Inc.

Price target over the last 5 years

History of analyst recommendation changes

e45a190c600ffc1d21807c84.Fz5BrANsrv9I8z8fXi2WMAul3GkmIlqZ_Xdk6TU1BEc.IF0k7nkmzbIK3g9dNhnFSknopABEaj3ozRUNrkJUXDJ2U3T8cCjJjAyEag~108bfe8f1ebf8e36677173fda64fea16

Analyst Recommendations on Exelixis, Inc.

Barclays Downgrades Exelixis to Equalweight From Overweight, Price Target is $25 MT
RBC Raises Price Target on Exelixis to $28 From $26, Keeps Outperform Rating MT
Barclays Adjusts Price Target on Exelixis to $25 From $24, Keeps Overweight Rating MT
BTIG Starts Exelixis With Buy Rating, $27 Price Target MT
Citigroup Initiates Exelixis at Buy Rating With $31 Price Target MT
Guggenheim Raises Exelixis' Price Target to $30 From $27, Keeps Buy Rating MT
JMP Securities Adjusts Price Target on Exelixis to $27 From $24, Maintains Market Outperform Rating MT
Oppenheimer Adjusts Exelixis Price Target to $29 From $25, Maintains Outperform Rating MT
SVB Securities Initiates Exelixis With Market Perform Rating, $18 Price Target MT
Barclays Adjusts Price Target on Exelixis to $24 From $25, Maintains Overweight Rating MT
Morgan Stanley Adjusts Price Target on Exelixis to $22 From $21, Maintains Equal-Weight Rating MT
RBC Lifts Exelixis' Price Target to $26 From $25, Keeps Outperform Rating MT
Morgan Stanley Trims Price Target on Exelixis to $21 From $22, Maintains Equalweight Rating MT
Wells Fargo Starts Exelixis at Overweight With $23 Price Target MT
RBC Lowers Exelixis Price Target to $25 From $27, Maintains Outperform Rating MT
Credit Suisse Starts Exelixis at Outperform With $29 Price Target MT
JMP Securities Adjusts Price Target on Exelixis to $24 From $25, Maintains Market Outperform Rating MT
Oppenheimer Adjusts Exelixis Price Target to $25 From $27, Maintains Outperform Rating MT
EF Hutton Adjusts Exelixis' Price Target to $24 From $28, Keeps Buy Rating MT
Oppenheimer Adjusts Exelixis Price Target to $27 From $29, Maintains Outperform Rating MT
Truist Securities Trims Price Target on Exelixis to $32 From $35, Maintains Buy Rating MT
JMP Securities Adjusts Price Target on Exelixis to $25 From $26, Maintains Market Outperform Rating MT
Morgan Stanley Adjusts Price Target on Exelixis to $22 From $23, Keeps Equalweight Rating MT
RBC Capital Lowers Exelixis' Price Target to $29 From $31, Keeps Outperform Rating MT
EF Hutton Starts Exelixis at Buy With $28 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
21
Last Close Price
22.49 USD
Average target price
26.63 USD
Spread / Average Target
+18.43%
High Price Target
32.35 USD
Spread / Highest target
+43.84%
Low Price Target
18 USD
Spread / Lowest Target
-19.96%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Exelixis, Inc.

Barclays
RBC Capital Markets
BTIG
Citigroup
Guggenheim
JMP Securities
Oppenheimer
SVB Securities LLC
Morgan Stanley
Wells Fargo Securities
Credit Suisse
EF Hutton
Truist Securities
Piper Sandler
BMO Capital
Jefferies & Co.
HC Wainwright
Needham & Co.
Goldman Sachs
Wolfe Research

Ratings for Exelixis, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. EXEL Stock
  4. Consensus Exelixis, Inc.